PHYSIOMICS PLC LS -004
Research PHYSIOMICS PLC LS -004 (RVW1) on Bullrun: market cap EUR 2.09M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRVW1
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 2.09M
- Financial periodFY2025
- RevenueGBP 784.01K
- Revenue growth44.3%
- Net income-GBP 415.25K
- Free cash flow-GBP 550.08K
Valuation Snapshot
latest market cap is EUR 2.09M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 784.01K | -GBP 415.25K | -GBP 550.08K | n/a | 0 | GBP 461.24K | n/a | GBP 692.17K |
| FY2024 | GBP 543.25K | -GBP 609.35K | -GBP 565.44K | n/a | 0 | GBP 191.07K | n/a | GBP 282.53K |
| FY2023 | GBP 597.35K | -GBP 477.26K | -GBP 273.22K | n/a | 0 | GBP 416.59K | n/a | GBP 531.72K |
| FY2022 | GBP 830.27K | -GBP 253.14K | -GBP 358.76K | n/a | 0 | GBP 687.67K | n/a | GBP 974.81K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 2.09M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About PHYSIOMICS PLC LS -004
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PHYSIOMICS PLC LS -004's market cap?
PHYSIOMICS PLC LS -004's market capitalization is EUR 2.09M.
What does PHYSIOMICS PLC LS -004 do?
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.